Compare Recursion Pharmaceuticals Inc (RXRX) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Stryker Corporation — how do they compare? Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.78B), while Stryker Corporation trades at $340.62 (market cap $133.18B). The key difference: Stryker Corporation is far larger — about 74.8× Recursion Pharmaceuticals Inc's market cap, and Stryker Corporation pays a 1.01% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SYK | |
|---|---|---|
Market Cap | $1.78B | $133.18B |
Sector | Health | Technology |
52-Week High | $6.79 | $394.34 |
52-Week Low | $2.84 | $282.58 |
Enterprise Value | $1.30B | $144.65B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.29, down 1.64% on the day, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, though revenue fell year-over-year. Financials show deep losses with a net income margin of -961.97% in 2026, but cash flow trends improved with net cash flow turning positive in 2025. Recent news highlights institutional stake increases and partnership advancements with Genentech.
The outlook remains challenged by persistent losses and slow revenue growth, offset by a solid cash runway into 2028 and partnership potential. Key risks include high cash burn and delayed commercial milestones, while 40% of analysts rate it a Buy, suggesting cautious optimism for long-term platform validation.
Stryker (SYK) trades at $347.21, down 0.27% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $379.44. The company reported strong Q2 2026 earnings with EPS of $3.69 beating estimates and 9% organic sales growth, reflecting recovery from a cyber incident. Valuation ratios like P/E of 35.98 and P/S of 5.19 indicate a premium, but profitability remains robust with a net income margin of 14.43% and ROE of 16.51%.
Outlook is positive due to earnings momentum and raised guidance, though risks include execution challenges from cyber costs and supply constraints. Analysts are overwhelmingly bullish with 74% buy ratings, suggesting upside potential, but investors should monitor margin pressures and competitive threats in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
